Progenra sees significant unmet medical need and market opportunities in developing products to treat cancer (by both direct and immune-based strategies), neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases, cardiovascular disease, and inflammatory diseases such as asthma and psoriasis. We use an exclusive research platform to identify novel, first in class breakthrough therapeutic medicines based on small molecule modulators of enzymes in the ubiquitin proteasome system and on novel PROTAC®s, which harness UPS ligases. Progenra has also developed a novel PROTAC® platform. Progenra’s investment during the last decade has mitigated some of the risks, and we stand to add great upside to existing pharmaceutical and biotechnology company ventures and to create new programs with interested parties. Progenra invites partnership, funding, and investment opportunities from both small and large institutions.
Please contact Progenra’s Business Development office for further discussion.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.